Risk Factors and the Role of Albumin-to-globulin Ratio in Idiopathic Granulomatous Mastitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

109 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-20

Study Completion Date

2022-05-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Albumin-to-globulin ratio (AGR) is an inflammation-based index that has been shown to have a role in many cancers and inflammatory diseases. Idiopathic granulomatous mastitis (IGM) is a rare inflammatory disease of the breast with a high recurrence rate. As a relatively new biomarker for inflammatory diseases, AGR's role in IGM recurrence has never been investigated in the literature. This study primarily investigates the possible risk factors for IGM recurrence and whether AGR can be used as a predictive factor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Idiopathic Granulomatous Mastitis Combination Therapy

NCT05361629

Idiopathic Granulomatous Mastitis

UNKNOWN NA

Could Intralesional Steroid be the Novel Treatment for Granulomatous Mastitis?

NCT04596046

Granulomatous Mastitis

COMPLETED NA

Granulomatous Mastitis Current Approach and Treatment

NCT02667132

Granulomatous, Mastitis

COMPLETED

Seroma of the Mammary Gland

NCT05899387

Seroma Breast Cancer Mastectomy +1 more

RECRUITING NA

Combined Intralesional Triamcinolone Injection With Whole Breast Detection Radical Surgery

NCT05281419

Refractory Granulomatous Lobular Mastitis

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients diagnosed with IGM on pathology reports between January 2016 and March 2021 were enrolled in the study and their medical records were analyzed retrospectively. The patients were divided into two groups: recurrence and non-recurrence. Clinical, demographic characteristics, and laboratory parameters were compared. The best cut-off value for significant factors in predicting recurrence was determined by receiver operating characteristic (ROC) analysis. Univariate and multivariate logistic regression analysis was used to determine the risk factors that are effective in IGM recurrence.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Granulomatous Mastitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

no recurrence

Patients who recovered after IGM treatment and had no signs of relapse

segmental mastectomy

Intervention Type PROCEDURE

The preferred method in the treatment of some patients diagnosed with IGM

recurrence

Patients whose symptoms reappear 3 months after IGM treatment

segmental mastectomy

Intervention Type PROCEDURE

The preferred method in the treatment of some patients diagnosed with IGM

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

segmental mastectomy

The preferred method in the treatment of some patients diagnosed with IGM

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Incision and Drainage

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patients with a pathologically confirmed diagnosis of granulomatous mastitis
* Patients over the age of 18
* Female patients

Exclusion Criteria

* Male patients
* Secondary granulomatous mastitis etiologies (tuberculous mastitis and Wegener's granulomatosis)
* Patients who do not have enough follow-up information
* Patients with missing data

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No